Tosatoxumab

N/A

Report date: 2023/07/17 16:04:00

Base Information

Drug NameTosatoxumab
Drug Alias NameAnti-S.aureus-mAbAnti-Staphylococcus-aureus-mAbAnti-S.aureus-monoclonal-antibodyAnti-Staphylococcus-aureusmonoclonal- antibodySalvecin +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAlpha-hemolysin inhibitors
TargetsAlpha-hemolysin
Therapy Area/IndicationsLung DiseasesPneumonia, Ventilator-AssociatedPneumonia, Staphylococcal +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUkraineTurkey +[15] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesKenta BiotechAridis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSerum Institute Of India Pvt LtdEmergent Biosolutions IncAridis Pharmaceuticals Inc +[5] 
Inactive CompaniesN/A
Active IndicationsLung DiseasesPneumonia, Ventilator-AssociatedPneumonia, Staphylococcal +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A